Cellular Dataset Partnerships

GSK And Relation Therapeutics Introduced Its MORGAN Platform

GSK and Relation Therapeutics expanded their collaboration to generate large-scale human cellular datasets and train AI models for drug target discovery. The agreement, worth up to $110 million, combines Relation’s Lab-in-the-Loop experimental workflows with models from its MORGAN platform to study how cells respond to genetic changes and drug interventions.

Relation will use techniques including tissue profiling, single-cell and spatial transcriptomics, sequencing, perturbation experiments and target validation, with machine learning applied to target identification and prioritization. The deal builds on earlier work between the companies in fibrotic diseases and osteoarthritis, where they combined human genetics, multi-omics and functional assays.

For drug developers, the partnership highlights the value of generating disease-specific biological data alongside model development. The approach could reduce dependence on heterogeneous public datasets while improving AI-supported target identification and experimental validation.

Open at source ↗